Navigation Links
REPEL-CV(TM) Adhesion Barrier Receives Endorsement of Kids With Heart
Date:8/7/2009

ISELIN, N.J., Aug. 7 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion products, announced today that REPEL-CV Bioresorbable Adhesion Barrier has received the endorsement of Kids With Heart National Association for Children's Heart Disorders, Inc. Michelle L. Rintamaki, Director of Kids With Heart, stated, "We want to inform parents of children with congenital heart defects about this new surgical device that reduces the risks associated with adhesions during repeat open-heart surgical procedures."

About Adhesions

Adhesions, or scar tissue, occur after virtually all open-heart surgical procedures, often resulting in the heart becoming attached to the sternum and other surrounding tissue surfaces. The presence of adhesions represents a prevalent and serious complication in secondary surgical procedures, increasing the patient risk, length and cost of the surgical procedure.

About REPEL-CV

REPEL-CV is a bioresorbable adhesion barrier film designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedure to reduce the extent and severity of adhesions. It was recently approved by the US Food and Drug Administration for use in pediatric patients who undergo staged open-heart surgical procedures.

About Kids With Heart NACHD, Inc.

The organization was formed in 1985 with the main mission of providing support, information, and education to the families of children living with congenital heart defects and to promote public awareness of the issues that these families live with on a day to day basis. It is a 501(c)3 organization entirely supported by volunteers.

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products. The company is primarily focused on the commercialization of REPEL-CV(TM) Bioresorbable Adhesion Barrier and the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technologies.

Statements in this press release that are not statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Reference is made to the company's Annual Report on Form 10-KSB for the year ended December 31, 2008, for a description of these, as well as other, risks and uncertainties.

www.kidswithheart.org


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
2. Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform
3. Cellix Ltd. Launches VenaEC Biochip for Flow-based Cell-adhesion Assays
4. FDA Approves SyntheMeds REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery
5. Novel Product for the Prevention of Post-Surgical Adhesion Formation Completes Phase I Clinical Study
6. Nanoengineered barrier invented to protect plastic electronics from water degradation
7. Barrier Therapeutics to Merge Into Stiefel Laboratories
8. Study Reveals Greatest Barrier to Green Supply Chain Initiatives
9. Physicists tweak quantum force, reducing barrier to tiny devices
10. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
11. Breaking barriers with nanoscale lasers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Irvine, ca (PRWEB) , ... October 12, 2017 ... ... for the Surgical Wound Market with the addition of its newest module, US ... the $1.2B market for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
Breaking Biology News(10 mins):